TherapeuticsMD (TXMD) Misses Q2 EPS by 3c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
TherapeuticsMD Announces Second Quarter 2018 Financial Results
July 30, 2018 6:15 AM EDT-Imvexxy early experience program underway; national launch to commence August 6, 2018-
-PDUFA target action date of October 28, 2018 for TX-001HR-
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative womens healthcare company, today announced its financial results for the quarter ended June 30, 2018.
Second Quarter and Recent Developments
Received FDA approval of Imvexxy (estradiol vaginal inserts) on May 29, 2018 for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to... More